Providing High Value, OTC Drugs Deserve Higher Profile In Health Care – CHPA
Executive Summary
While Rx drug pricing is under attack by Congress, White House and consumer and public health advocacy groups, OTC drugs' value isn't gaining a higher profile. "Our health care system undervalues the contribution of our industry's products," says CHPA chief Scott Melville. Trade group conducts “Value of OTC Medicines" study for reasons including raising the profile of consumer health products in the US health care system.
You may also be interested in...
Symptoms Change But Savings OTC Drugs Deliver For US Health Care Spending Continue Growing
Substantially more consumers in 2022 report sleep issues, allergies and skin problems than in 2018 while using quit smoking aids has dropped, according to CHPA’s latest “Value of OTC Medicines” survey. Average annual household spending on OTCs is $645.
India Proposes OTC List In Draft Rule Lacking Clarity On Pricing, Switching Pathway
India puts out rules for first set of over-the-counter drugs but provides no specifics on the pricing policy for such products or the wider switching pathway. Can the framework foster responsible self-medication and help reap value for patients in a market where the oversight of trade channels for sale of prescription-based drugs is lax?
US Consumers Know Pain, And How To Use Acetaminophen For It – CHPA Survey
While self-reported pain is up more than 10%, consumers are more educated on safe pain management using acetaminophen since CHPA's previous survey in 2019.